GlassScriptPhysician profile
Jeffrey Alan West
NPI 1700829272
$6,245.98
in general payments reported to CMS, 2019-2025
22 companies · $1,181 in 2025
The $1,181 reported for 2025 was more than what 82% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $705 · 2020: $342 · 2021: $571 · 2022: $852 · 2023: $728 · 2024: $1,866 · 2025: $1,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,044 · Travel and Lodging: $731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,043.86 |
| Travel and Lodging | $731.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $1,210.55 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $989.90 | 2021-2025 | Dupixent |
| Optinose US, INC. | $935.21 | 2019-2024 | |
| Genzyme Corporation | $618.38 | 2020-2025 | |
| Glaxosmithkline, LLC. | $601.36 | 2021-2025 | Nucala |
| Stryker Corporation | $455.34 | 2019-2025 | Scopis Ent |
| Neurent Medical Limited | $332.92 | 2022-2025 | Neuromark Radiofrequency Console, Neuromark System |
| Acclarent, INC | $251.71 | 2019-2023 | Acclarent Aera |
| Sanofi-Aventis U.S. LLC | $166.11 | 2020-2021 | |
| Medtronic, INC. | $164.88 | 2024-2025 | Ligasure, Propel, Sinuva |
| Alk-Abello, INC | $147.03 | 2019-2022 | |
| Smith+Nephew, INC. | $120.23 | 2024 | Halo, Coblation, Tula |
| Kaleo, INC. | $65.40 | 2020-2021 | |
| Hikma Pharmaceuticals USA | $29.23 | 2023-2025 | Ryaltris |
| Axogen | $28.46 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $22.91 | 2019 | |
| Davol INC. | $21.59 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $20.77 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $19.89 | 2019 | |
| Merck Sharp & Dohme LLC | $17.99 | 2021 | |
| Acelrx Pharmaceuticals, INC. | $13.36 | 2019 | |
| Phadia US INC. | $12.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey West listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.